These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7034048)

  • 21. Vasodilator therapy of congestive heart failure.
    Cohn JN
    Adv Intern Med; 1980; 26():293-315. PubMed ID: 6784453
    [No Abstract]   [Full Text] [Related]  

  • 22. Cardiocirculatory effects of afterload reduction with oral trimazosin in severe chronic congestive heart failure.
    Awan NA; Hermanovich J; Whitcomb C; Skinner P; Mason DT
    Am J Cardiol; 1979 Jul; 44(1):126-31. PubMed ID: 453037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the vasodilator prazosin and the selective beta1 agonist prenalterol on rest and exercise haemodynamics in CHF.
    Hutton I; Tweddel AC; Bastian BC; Murray RG
    Acta Med Scand Suppl; 1981; 652():163-8. PubMed ID: 6120615
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure.
    Wilson RM; De Silva DS; Sato K; Izumiya Y; Sam F
    Hypertension; 2009 Sep; 54(3):583-90. PubMed ID: 19620510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ambulatory long-term vasodilator therapy for chronic refractory heart failure: hemodynamic evaluation and clinical response.
    Saito S; Ichikawa M; Ozawa Y; Yumikura S; Nagasawa M; Hibiya K; Tamura Y; Tomobe K; Hatano M
    Jpn Circ J; 1984 Apr; 48(4):350-6. PubMed ID: 6425526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure.
    Massie BM; Kramer B; Shen E; Haughom F
    Br Heart J; 1981 Apr; 45(4):376-84. PubMed ID: 7225252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of vasodilator drugs on exercise performance in cardiac failure. Comparison of hydralazine and prazosin.
    Fitchett DH; Pathé M; Pardy R; Despas P
    Br Heart J; 1980 Aug; 44(2):215-20. PubMed ID: 7426176
    [No Abstract]   [Full Text] [Related]  

  • 28. Noninvasive assessment of left ventricular effects of hydralazine in heart failure.
    Deglin SM; Jain AC; Harris WS
    Cardiology; 1980; 66(4):193-8. PubMed ID: 7448835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemodynamic and metabolic effects of vasodilator therapy for heart failure in acute myocardial infarction.
    Kodama K; Koretsune Y; Nanto S; Taniura K
    Jpn Circ J; 1984 Apr; 48(4):380-7. PubMed ID: 6425527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vasodilators in left ventricular failure.
    Camerini F; Mestroni L; Neri R; Humar F
    G Ital Cardiol; 1984 Sep; 14(9):685-93. PubMed ID: 6510623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and use of vasodilators in the management of congestive heart failure.
    Lakier JB; Khaja F; Stein PD
    Am Heart J; 1979 Apr; 97(4):519-26. PubMed ID: 371379
    [No Abstract]   [Full Text] [Related]  

  • 32. Outflow resistance as a regulator of left ventricular performance.
    Franciosa JA
    Angiology; 1978 May; 29(5):393-401. PubMed ID: 655470
    [No Abstract]   [Full Text] [Related]  

  • 33. Hemodynamic effects of molsidomine, isosorbide dinitrate, and nifedipine at rest and during exercise.
    Schartl M; Dougherty C; Rutsch W; Schmutzler H
    Am Heart J; 1985 Mar; 109(3 Pt 2):649-53. PubMed ID: 3838401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure.
    Steimle AE; Stevenson LW; Chelimsky-Fallick C; Fonarow GC; Hamilton MA; Moriguchi JD; Kartashov A; Tillisch JH
    Circulation; 1997 Aug; 96(4):1165-72. PubMed ID: 9286945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vasodilator therapy for congestive heart failure--new use for old drugs.
    McAlpin RN
    JAMA; 1978 Aug; 240(5):461-2. PubMed ID: 660892
    [No Abstract]   [Full Text] [Related]  

  • 36. Role of isosorbide dinitrate in management of chronic congestive heart failure.
    Parmley WW
    Am Heart J; 1985 Jul; 110(1 Pt 2):264-8. PubMed ID: 3893081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure.
    Massie B; Chatterjee K; Werner J; Greenberg B; Hart R; Parmley WW
    Am J Cardiol; 1977 Nov; 40(5):794-801. PubMed ID: 411364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vasodilator therapy for congestive heart failure.
    Fouad FM
    Cardiovasc Clin; 1981; 12(2):127-35. PubMed ID: 7344769
    [No Abstract]   [Full Text] [Related]  

  • 39. Improvement in exercise haemodynamics by isosorbide dinitrate in patients with severe congestive cardiac failure secondary to ischaemic heart disease.
    Stephens J; Camm J; Spurrell R
    Br Heart J; 1978 Aug; 40(8):832-7. PubMed ID: 687484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vasodilators in heart failure secondary to coronary artery disease.
    Parmley WW; Rouleau JL; Chatterjee K
    Am Heart J; 1982 Apr; 103(4 Pt 2):625-32. PubMed ID: 7064804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.